

## REMARKS

The above-identified application is a continuation application under 37 C.F.R. §1.53(b) of copending application U.S. Serial No. 09/208,786, filed December 10, 1998. The specification has been amended hereinabove to insert the continuation data of U.S. Serial No. 09/208,786.

Claims 1-80 have been canceled without prejudice and new claims 81-82 have been added. Support for new claims 81-82 may be found in the specification *inter alia* at page 22, lines 23-31. Applicant respectfully requests entry of this Preliminary Amendment which is submitted in the format required under 37 C.F.R. § 1.121 together with a marked-up version of the replacement paragraphs/sections.

Accordingly upon entry of the Preliminary Amendment, claims 81-82 will be pending and under examination in the subject application.

Respectfully submitted,

Dated: Oct. 29, 2001

By: Elizabeth M. Wieckowski  
Elizabeth M. Wieckowski  
Registration No. 42,226

KENYON & KENYON  
One Broadway  
New York, New York 10004  
(212) 425-7000 (telephone)  
(212) 425-5288 (facsimile)

Version with markings to show changes made:

The title, at page 1, lines 1-2:

--METHOD FOR ISOLATING CELLS EXPRESSING FLK-2 RECEPTORS AND ISOLATED POPULATIONS OF CELLS THAT EXPRESS FLK-2 [TOTIPOTENT HEMATOPOIETIC STEM CELL] RECEPTORS [AND THEIR LIGANDS]--

At page 1, line 4 lines 4-12:

--This application is a continuation of copending application U.S. Serial No. 09/208,786, filed December 10, 1998, which is a continuation of U.S. Serial No. 09/021,324 filed February 10, 1998, now U.S. Patent 5,912,133, which is a continuation of U.S. Serial No. 08/601,891 filed February 15, 1996, now U.S. Patent No. 5,747,651, which is a divisional of U.S. Serial No. 08/252,498 filed October 31, 1994, now abandoned, which is a divisional of U.S. Serial No. 08/055,269 filed April 30, 1993, now U.S. Patent No. 5,367,057, which is a divisional of U.S. Serial No. 07/977,451 filed November 19, 1992, now U.S. Patent No. 5,270,458, which is a continuation-in-part of [unassigned serial number] U.S. Serial No. 07/975,049 filed November 12, 1992, now abandoned, which is a continuation-in-part of [serial number] U.S. Serial No. 07/906,397 filed June 26, 1992, now U.S. Patent No. 5,621,090, which is [is] a continuation-in-part of [serial number] U.S. Serial No. 07/813,593 filed December 24, 1991, now U.S. Patent No. 5,185,438, which is a continuation-in-part of [serial number] U.S. Serial No. 07/793,065 filed November 15, 1991, now abandoned, which is a continuation-in-part of [serial number] U.S. Serial No. 07/728,913 filed June 28, 1991, now abandoned, which is a continuation-in-part of [serial number] U.S. Serial No. 07/679,666 filed April 2, 1991, now abandoned, all of which are incorporated herein by reference.--

At page 47, line 34 through page 48, line 6:

--C. Purified Flag-Flk2 protein labelled with Na<sup>125</sup> via the Chloramine T method is used to

[asses] assess the ability of the soluble extracellular domain of the Flk-2 receptor to bind transmembrane form of the Flk2 ligand in cultured stromal lines. The labelled protein is added to monolayers of stromal cells on ice for 2 hr in the presence or absence of excess unlabelled protein. Specific binding is calculated by subtracting counts bound in the presence of excess unlabelled protein from the total counts bound.--